Healthcare Industry News: neuromodulation
News Release - May 18, 2009
Cyberonics Names Bryan D. Olin, Ph.D. Vice President, QualityHOUSTON, May 18 (Healthcare Sales & Marketing Network) -- Cyberonics, Inc. (Nasdaq: CYBX ) today announced that Bryan D. Olin, Ph.D., joined Cyberonics as Vice President, Quality, effective on May 18, 2009. Dr. Olin will lead all of the company's quality programs.
Dr. Olin joins Cyberonics from Zeltiq Aesthetics, an aesthetics device firm in California, where he served as Senior Director, Quality Assurance, since October 2007. Prior to Zeltiq, Dr. Olin was employed as Executive Director, Failure Analysis, Product Quality Services and Product Safety with Cordis Corporation, a Johnson & Johnson company. Dr. Olin spent five years with another Johnson & Johnson company, LifeScan, as the Manager, Statistical Engineering; Senior Program Manager, QA; Director, Complaint Handling and QA Laboratories; and Director, Clinical Biometrics and Complaint Management. Dr. Olin began his business career as a Statistician for Procter & Gamble, providing statistical support to a diverse set of internal clients in R&D and manufacturing.
"Bryan brings substantial expertise in quality management that will be helpful in all aspects of our regulated business, including manufacturing and product development," said Dan Moore, Cyberonics' President and Chief Executive Officer. "He has extensive experience with regulatory inspections and submissions, complaint handling, CAPAs and clinical study design. We are pleased to have Bryan joining our team to lead the global quality system and programs."
Dr. Olin received a B.S. in Mathematics from the University of Kansas. He was awarded a Masters of Science and his Ph.D. in Statistics from Iowa State University. Dr. Olin served as an Adjunct Assistant Professor of Industrial Pharmacy at the University of Cincinnati for three years.
About Cyberonics, Inc. and VNS Therapy(TM)
Cyberonics, Inc. (NASDAQ:CYBX ) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.